549 related articles for article (PubMed ID: 30982348)
1. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Ashina M; Tepper S; Brandes JL; Reuter U; Boudreau G; Dolezil D; Cheng S; Zhang F; Lenz R; Klatt J; Mikol DD
Cephalalgia; 2018 Sep; 38(10):1611-1621. PubMed ID: 29984601
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
Hirata K; Sakai F; Takeshima T; Imai N; Matsumori Y; Yoshida R; Numachi Y; Peng C; Mikol DD; Cheng S
J Headache Pain; 2021 Sep; 22(1):110. PubMed ID: 34537006
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
8. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
[TBL] [Abstract][Full Text] [Related]
9. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
12. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
[TBL] [Abstract][Full Text] [Related]
15. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
[TBL] [Abstract][Full Text] [Related]
16. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
17. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
Wang SJ; Roxas AA; Saravia B; Kim BK; Chowdhury D; Riachi N; Tai MS; Tanprawate S; Ngoc TT; Zhao YJ; Mikol DD; Pandhi S; Wen S; Mondal S; Tenenbaum N; Hours-Zesiger P
Cephalalgia; 2021 Nov; 41(13):1285-1297. PubMed ID: 34171973
[TBL] [Abstract][Full Text] [Related]
18. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
[TBL] [Abstract][Full Text] [Related]
19. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
20. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
Ferrari MD; Reuter U; Goadsby PJ; Paiva da Silva Lima G; Mondal S; Wen S; Tenenbaum N; Pandhi S; Lanteri-Minet M; Stites T
J Neurol Neurosurg Psychiatry; 2022 Mar; 93(3):254-262. PubMed ID: 34845002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
